Crohn's Disease Clinical Trial
Verified date | March 2017 |
Source | Beth Israel Deaconess Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The human immune system is usually tolerant of the millions of beneficial commensal bacteria
(the microbiome), which colonize the healthy intestinal tract. In contrast, patients with
Inflammatory Bowel Disease (IBD) may play host to an imbalanced mix of such intestinal
bacteria, which initiates abnormal immune responses in susceptible individuals. The
resulting inflammation that occurs in the gastrointestinal tract damages the intestinal
lining, leading to symptoms (such as intractable diarrhea, pain or weight loss), heightened
cancer risk, other serious complications with substantial morbidity and even death. Current
therapies for IBD focus on suppressing the excessive immune response to these bacteria, but
have major side effects and do not address any role of the microbiome in disease
development.
The investigators hypothesize that there is heightened intraluminal generation of
pro-inflammatory factors by luminal "pathogenic" bacteria, such as extracellular nucleotides
and purinergic derivatives, which trigger host immune cells. This results in loss of
suppressive T regulatory cells with unrestrained immune cell deviation to pathogenic T
helper cells that cause inflammatory responses. The investigators' proposal is that
correcting the disease-provoking microbiome would beneficially improve gut microbial
diversity, alter immune responses elicited in patients by such microbial products of
pathogenic bacteria, and ultimately limit and suppress disease activity.
To test the hypothesis, the investigators propose to enroll patients with active Crohn's
Disease, and introduce the microbiome of healthy and unrelated individuals to patient's
intestinal tract, via fecal biotherapy (FBT) with all applicable safety measures. The
investigators propose to comprehensively test the effects of FBT on the host microbiome,
determine microbial production of inflammatory nucleotides and derivatives, which the
investigators suggest might impact the host immune response and disease activity in patients
with IBD.
Status | Completed |
Enrollment | 22 |
Est. completion date | November 2016 |
Est. primary completion date | November 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria (Patients): - CD confirmed by biopsy for > 3 months duration - Active disease (Harvey-Bradshaw Index > 5 - Failed standard therapy with; stable doses of 5-ASA >2 weeks; thiopurines >3 months; or is steroid dependent at a dose <20mg/d; (inability to taper off steroid for longer than 1 week) - Stable medication regimen for >2 weeks. - Age > 18 years old Exclusion Criteria (Patients): - Diagnosis of indeterminate colitis, or proctitis alone - Severe or fulminate colitis - Women who are pregnant or nursing - Patients who are unable to give informed consent - Patients who are unable or unwilling to undergo colonoscopy with moderate sedation (>ASA class II) - Patients who have previously undergone FMT - Patients who have a confirmed malignancy or cancer - Patients who are immunocompromised - Treatment within last 12 weeks with cyclosporine, tacrolimus, infliximab, adalimumab, certolizumab, natalizumab, thalidomide - Antibiotic use within 2-months of start date - Participation in a clinical trial in the preceding 30 days or simultaneously during this trial - Probiotic use within 30 days of start date - Rectal therapy within 14 days of start date - Decompensated cirrhosis - Congenital or acquired immunodeficiencies - Other comorbidities including: - Diabetes mellitus, cancer, systemic lupus, must be able to tolerate conscious sedation with colonoscopy - Chronic kidney disease as defined by a GFR <60mL/min/1.73m2 44 - History of rheumatic heart disease, endocarditis, or valvular disease due to risk of bacteremia from colonoscopy - Steroid dose >20mg/day |
Country | Name | City | State |
---|---|---|---|
United States | Beth Israel Deaconess Medical Center | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Beth Israel Deaconess Medical Center | Brigham and Women's Hospital, The Broad Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety of FMT in patients with Crohn's disease, as measured by number and nature of adverse events | 24 weeks | ||
Primary | Recipients' fecal microbial diversity after FMT, when compared to baseline | 12 weeks | ||
Secondary | Recipients' fecal microbial diversity at 4 and 8 weeks after FMT, when compared to baseline | 8 weeks | ||
Secondary | Mean change in Harvey Bradshaw Index (HBI) score | 12 weeks | ||
Secondary | Percentage of patients in clinical remission (those with an HBI score at week 12 <5) | 12 weeks | ||
Secondary | Mean change in Short Inflammatory Bowel Disease Questionnaire (sIBDQ) score | 12 weeks | ||
Secondary | Percentage of patients in endoscopic remission (CDEIS score <3) | 12 weeks | ||
Secondary | Percentage of patients with mucosal healing (CDEIS score <1) | 12 weeks | ||
Secondary | Mean change in CRP levels | 12 weeks | ||
Secondary | Mean change in Crohn's Disease Endoscopic Index of Severity (CDEIS) score | 12 weeks | ||
Secondary | Tolerability score | 2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03815851 -
Relationship Between Prophylactic Drainage and Postoperative Complications (PPOI) in Crohn's Patients After Surgery
|
N/A | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Completed |
NCT02883452 -
A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis
|
Phase 1 | |
Recruiting |
NCT04777656 -
Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients.
|
Phase 3 | |
Terminated |
NCT03017014 -
A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
|
||
Recruiting |
NCT06053424 -
Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease
|
Phase 1 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Terminated |
NCT02882841 -
MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients
|
N/A | |
Not yet recruiting |
NCT02858557 -
The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases
|
N/A | |
Terminated |
NCT02417974 -
Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)
|
Phase 2 | |
Completed |
NCT03010787 -
A First Time in Human Study in Healthy Volunteers and Patients
|
Phase 1 | |
Completed |
NCT02542917 -
Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study
|
||
Active, not recruiting |
NCT02316678 -
Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics
|
N/A | |
Completed |
NCT02197780 -
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
|
N/A | |
Completed |
NCT02154425 -
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
|
Phase 1 | |
Completed |
NCT02193048 -
Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
|
||
Completed |
NCT02265588 -
Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD).
|
N/A | |
Recruiting |
NCT02395354 -
Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease
|
N/A | |
Completed |
NCT01958827 -
A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease
|
Phase 3 |